RHEB

Ras homolog, mTORC1 binding

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
RHEB Y35N1
Sirolimus	Malignant Kidney Neoplasm	Predictive	D	Supports Resistance	3	submitted	EID6340 Analysis of cancer genome databases led to identification of a recurrent point mutation in RHEB (Y35N), reported in RCC and in several other cancers. Y35N RHEB mutation in ccRCC causes mTORC1 hyperact… (full text at CIViC) PMID 26255626 · Ghosh et al., 2015 · Open in CIViC	civic

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved6 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Refractory Cancers (RC) - Peripheral T-Cell Lymphoma (PTCL) RC-PTCL	Peripheral T-Cell Lymphoma, Not Otherwise Specified

Literature

Data not yet available

No publication linked to this gene yet.